Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The biology of osteocytes.Curr Osteoporos Rep. 2007; 5: 81-86
- The amazing osteocyte.J Bone Miner Res. 2011; 26: 229-238
- Building bone to reverse osteoporosis and repair fractures.J Clin Invest. 2008; 118: 421-428
- Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety.Toxicol Pathol. 2002; 30: 312-321
- Of mice and men: divergent risks of teriparatide-induced osteosarcoma.Osteoporos Int. 2010; 21: 1041-1045
- Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.Ann N Y Acad Sci. 2007; 1117: 209-257
- Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.J Med Genet. 2006; 43: 315-325
- Emerging roles of cysteine cathepsins in disease and their potential as drug targets.Curr Pharm Des. 2007; 13: 387-403
- Cathepsin K inhibitors: a novel target for osteoporosis therapy.Clin Pharmacol Ther. 2008; 83: 172-176
- Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.Science. 1996; 273: 1236-1238
- The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.Bioorg Med Chem Lett. 2008; 18: 923-928
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.J Bone Miner Res. 2010; 25: 937-947
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.J Bone Miner Res. 2011; 26: 242-251
- Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?.J Bone Miner Res. 2011; 26: 239-241
- Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women.Bone. 2007; 40: 723-729
- GLP-2 significantly increases hip BMD in postmenopausal women: a 120-day study.J Bone Miner Res. 2007; 22: S37
- GLP-2 acutely uncouples bone resorption and bone formation in postmenopausal women.J Bone Miner Res. 2008; 23: S474
- Nitroglycerine improves bone mineral density, bone geometry, and bone strength: results from a two-year randomized controlled trial.J Bone Miner Res. 2010; 25: S77
- Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.J Bone Miner Res. 2004; 19: 1512-1517
- Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group.N Engl J Med. 1998; 339: 733-738
- Nitric oxide and bone.Ann N Y Acad Sci. 2010; 1192: 391-403
- Nitric oxide: new evidence for novel therapeutic indications.Expert Opin Pharmacother. 2008; 9: 1935-1954
- Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.Ann N Y Acad Sci. 2007; 1117: 283-297
- Use of organic nitrates and the risk of hip fracture: a population-based case-control study.J Clin Endocrinol Metab. 2010; 95: 1924-1931
- Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.J Clin Endocrinol Metab. 2009; 94: 3356-3364
- Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial.JAMA. 2011; 305: 800-807
- Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med. 2001; 344: 1434-1441
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.Arch Intern Med. 2005; 165: 1762-1768
- In vivo analysis of Wnt signaling in bone.Endocrinology. 2007; 148: 2630-2634
- Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.Endocrinology. 2007; 148: 2635-2643
- Bone mineral density in sclerosteosis; affected individuals and gene carriers.J Clin Endocrinol Metab. 2005; 90: 6392-6395
- Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women.J Bone Miner Metab. 2007; 22: S37
- Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.J Bone Miner Res. 2009; 24: 171-178
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis.Nat Med. 2010; 16: 308-312
- Effect of selective serotonin reuptake inhibitors on the risk of fracture.Arch Intern Med. 2007; 167: 188-194
- Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass.Cell. 2000; 100: 197-207
- Bone: serotonin, leptin and the central control of bone remodeling.Nat Rev Rheumatol. 2009; 5: 657-658
- Serotonin rising–the bone, brain, bowel connection.N Engl J Med. 2009; 360: 957-959
- The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics.Subcell Biochem. 2007; 45: 139-167
- Haploinsufficiency of parathyroid hormone-related peptide results in abnormal postnatal bone development.Dev Biol. 1996; 175: 166-176
- Short-term parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.J Clin Endocrinol Metab. 2003; 88: 569-575
- Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.J Clin Endocrinol Metab. 2010; 95: 1279-1287
Article info
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
